SCHEDULE: Suvretta Capital Discloses 6.6% Stake in Capricor

Suvretta Capital Management and its affiliates have reported a passive beneficial ownership of 6.6% in Capricor Therapeutics, Inc. common stock.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen collectively reported beneficial ownership of Capricor Therapeutics, Inc. common stock.
• Suvretta Capital Management, LLC and Aaron Cowen each beneficially own 3,417,891 shares, representing 6.6% of the class.
• Averill Master Fund, Ltd. beneficially owns 2,917,420 shares, representing 5.6% of the class.
• All reporting persons hold shared voting and dispositive power over their respective reported shares.
• Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC.
• Averill Master Fund, Ltd. is an advisory client of Suvretta Capital Management, LLC and is the only advisory client deemed to beneficially own more than 5% of the Common Stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, primarily due to the disclosure of significant institutional ownership, which can be interpreted as a vote of confidence in the company, although it provides no operational or financial updates.

Positives

• The disclosure of a significant stake by an institutional investor like Suvretta Capital Management, LLC, and its affiliates, may signal confidence in Capricor Therapeutics, Inc.'s long-term prospects.

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G provide transparency into significant ownership changes, which can sometimes precede increased market attention or strategic shifts within the biotechnology sector. The involvement of a prominent investment adviser like Suvretta Capital Management suggests a calculated position in Capricor Therapeutics, Inc.

Stakeholder Impact

• Shareholders may view the significant institutional investment as a positive signal, potentially influencing market sentiment and the company's stock price.

Key Dates

Recommendation

The filing indicates significant institutional interest in Capricor Therapeutics, Inc. by Suvretta Capital Management and its affiliates. While this is a positive signal, the Schedule 13G itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor for further company-specific news or strategic developments that could impact performance.

Keywords

Capricor Therapeutics, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Beneficial Ownership, Common Stock, Institutional Investment, Schedule 13G